Shattuck Labs reported its financial results for the second quarter ended June 30, 2025, with a cash balance of approximately $50.5 million as of that date. This cash balance does not include the anticipated net proceeds from the private placement announced on August 5, 2025.
The company successfully submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) for SL-325. IND clearance is expected in the third quarter of 2025, a critical step towards initiating human clinical trials.
Shattuck Labs is on track to dose the first participant in its Phase 1 clinical trial for SL-325 in healthy volunteers during the third quarter of 2025, with trial completion expected in the second quarter of 2026. The anticipated total proceeds from the private placement, combined with current cash, are expected to fund operations into 2029.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.